FDA’s CDER es­tab­lish­es new cen­ter of ex­cel­lence fo­cused on quan­ti­ta­tive med­i­cine

The FDA is strength­en­ing its fo­cus on us­ing math­e­mat­i­cal sim­u­la­tion and mod­el­ing to guide drug de­vel­op­ment with a new cen­ter of ex­cel­lence housed in the Cen­ter for Drug Eval­u­a­tion and Re­search, the agency an­nounced Mon­day.

The Quan­ti­ta­tive Med­i­cine Cen­ter of Ex­cel­lence will be tasked with fa­cil­i­tat­ing the ap­pli­ca­tions of quan­ti­ta­tive med­i­cine (QM) as it evolves. QM has been used across sev­er­al dif­fer­ent ar­eas, in­clud­ing bio­mark­er-end­point de­vel­op­ment, clin­i­cal tri­al sim­u­la­tions, as well as ma­chine learn­ing and ar­ti­fi­cial in­tel­li­gence. It’s hap­pen­ing as the FDA fo­cus­es more on us­ing math­e­mat­i­cal sim­u­la­tions in drug de­vel­op­ment. The agency in 2022 wrapped up a suc­cess­ful pi­lot pro­gram that gave spon­sors ad­di­tion­al ac­cess to the FDA to aid in mod­el-in­formed drug de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER